Research Article

Identification of Virulence Factors Genes in *Escherichia coli* Isolates from Women with Urinary Tract Infection in Mexico

Daniela A. López-Banda,¹ Erika M. Carrillo-Casas,²
Margarita Leyva-Leyva,² Gabriel Orozco-Hoyuela,³ Ángel H. Manjarrez-Hernández,⁴
Sara Arroyo-Escalante,² David Moncada-Barrón,⁵ Silvia Villanueva-Recillas,⁵
Juan Xicohtencatl-Cortes,⁶ and Rigoberto Hernández-Castro¹

¹ Department of Ecology of Pathogen Agents, Hospital General “Dr. Manuel Gea González”, 14080 Tlalpan, DF, Mexico

² Department of Molecular Biology and Histocompatibility, Hospital General “Dr. Manuel Gea González”, 14080 Tlalpan, DF, Mexico

³ Institute of Cell Physiology, Universidad Nacional Autónoma de México, 04510 Coyoacán, DF, Mexico

⁴ Department of Public Health, Universidad Nacional Autónoma de México, 04510 Coyoacán, DF, Mexico

⁵ Clinical Laboratory, Hospital General “Dr. Manuel Gea González”, 14080 Tlalpan, DF, Mexico

⁶ Department of Infectology, Hospital Infantil de México “Federico Gómez”, 06720 Cuauhtémoc, DF, Mexico

Correspondence should be addressed to Rigoberto Hernández-Castro; rigo31@yahoo.com

Received 11 February 2014; Accepted 20 April 2014; Published 5 May 2014

Academic Editor: Angel Cataldi

Copyright © 2014 Daniela A. López-Banda et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

E. coli isolates (108) from Mexican women, clinically diagnosed with urinary tract infection, were screened to identify virulence genes, phylogenetic groups, and antibiotic resistance. Isolates were identified by MicroScan4 system; additionally, the minimum inhibitory concentration (MIC) was assessed. The phylogenetic groups and 16 virulence genes encoding adhesins, toxins, siderophores, lipopolysaccharide (LPS), and invasins were identified by PCR. Phylogenetic groups distribution was as follows: B1 9.3%, A 30.6%, B2 55.6%, and D 4.6%. Virulence genes prevalence was *ecp* 98.1%, *fimH* 86.1%, *traT* 77.8%, *sfa/focDE* 74.1%, *papC* 62%, *iutA* 48.1%, *fyuA* 44.4%, *focG* 2.8%, *sfaS* 1.9%, *hlyA* 7.4%, *cnf-1* 6.5%, *cdt-B* 0.9%, *cvaC* 2.8%, *ibeA* 2.8%, and *rfa* 0.9%. Regarding antimicrobial resistance it was above 50% to ampicillin/sulbactam, ampicillin, piperacillin, trimethoprim/sulfamethoxazole, ciprofloxacin, and levofloxacin. Uropathogenic *E. coli* clustered mainly in the pathogenic phylogenetic group B2. The isolates showed a high presence of siderophores and adhesion genes and a low presence of genes encoding toxins. The high frequency of *papC* gene suggests that these isolates have the ability to colonize the kidneys. High resistance to drugs considered as first choice treatment such as trimethoprim/sulfamethoxazole and fluoroquinolones was consistently observed.

1. Introduction

Urinary tract infections (UTI) are one of the most common infections worldwide. Uropathogenic *Escherichia coli* (UPEC) is the primary pathogen causing UTIs; it colonizes the human intestine a few hours after birth and is considered part of the normal microbiota. However, it can cause various diseases such as diarrhea, UTI, and meningitis [1]. It is classified into three groups: (i) commensal, (ii) intestinal pathogenic, and (iii) extraintestinal pathogenic [2], and phylogenetically it has been classified into four classic groups

(A, B1, B2, and D) [3]. Uropathogenic *E. coli* is located within the extraintestinal pathogenic *E. coli* (ExPEC), classified primarily into the phylogenetic group B2 and to a lesser extent to group D, whereas commensal strains are within the phylogenetic groups A and B1 [4–8].

The ability of *E. coli* to colonize different anatomical sites is due in part to genome plasticity and remodeling by acquisition or loss of genetic material from which it acquired resistance or virulence factors. Therefore, horizontal transfer is an important factor in the evolution and adaptation of *E. coli* to different niches [9, 10]. The interaction between

bacteria and epithelial cells is a multifactorial and complex phenomenon which involves several adhesins produced according to the stage of infection, while adherence to epithelial cells is essential for successful colonization and establishment; the expression of other genes encoding toxins, siderophores, lipopolysaccharide (LPS), capsule, and invasins determines the disease severity and the strain's virulence [8]. UPEC strains can cause acute infections and recurrent infections that do not respond to common antimicrobial treatments. UTI treatment generally includes β -lactam antibiotics, fluoroquinolones, or trimethoprim/sulfamethoxazole [11–13] but may vary according to patient age, sex, Pathogen involved, course of disease, and the urinary tract anatomic area involved [5]. The increased resistance may be related to changes in the bacterial genome by mutation or acquisition by horizontal transfer of an extrachromosomal or chromosomal material [14–16].

Urinary tract successful invasion depends on the bacteria virulence, inoculum size, and the host's defense mechanisms [18]. However, women have higher UTI's prevalence and incidence mainly due to their anatomical characteristics such as the proximity between the anus and the urethral opening, hormone effects, and changes in the genital microbiota [14, 19]. Clinically a UTI is defined by a bacteriuria with a count in midstream urine culture $\geq 10^5$ CFU/mL and pyuria or the presence of white blood cells in the urine, more than five leukocytes per field [19].

Globally it is estimated that about 150 million UTIs occur annually [20]. In the United States and Spain the current situation and treatment of urinary tract infections had been thoroughly described [6–8, 18]; it is estimated that 11% of women experience at least one diagnosis of urinary tract infection (UTI) per year, and 60% of women will have or have had an UTI or more during their lifetime [4]. In Mexico UTI's status has not been described. However, to our knowledge it is *E. coli* one of the pathogenic agents of UTI and it is more frequent in women, with high incidence and prevalence, representing a costly problem for the health sector [4, 21]. In 2008, 3,244,994 cases were reported, which represents an incidence of 3,041.7/100,000 inhabitants, from which 75.6% (2,453,608/100,000 inhabitants) were women, representing an incidence of 4,508.6/100,000.

The present study aimed to describe the profile of *E. coli* from Mexican women with urinary tract infection by the identification of virulence genes (*fimH*, *papC*, *sfa/focDE*, *sfaS*, *focG*, *ecpA*, *ecpR-B*, *hlyA*, *cnf-1*, *cdt-B*, *cvaC*, *iutA*, *ibeA*, *rfa*, *trtA*, and *fyuA*), phylogenetic group, and their resistance to antibiotics to guide better diagnosis and treatment of UTI.

2. Material and Method

2.1. Bacteria and Culture. Bacterial isolates (108) were obtained from urine samples from women diagnosed with acute urinary tract infection and confirmed by the clinical laboratory of the General Hospital "Dr. Manuel Gea Gonzalez" during 2008 and until 2010. All samples with counts over 100,000 UFC/mL were included. Patients were within an age range between 12 and 58 years and mean age

TABLE 1: PCR primer for each virulence factor. Primer sequence was taken from Johnson and Stell, 2000 [5] and Blackburn et al., 2009 [17].

Genes	Primer (5'-3')
<i>ecpA</i>	TGA AAA AAA AGG TTC TGG CAA TAG C CGC TGA TGA GGA GAA AGT GAA
<i>ecpRB</i>	GTC ACA TGG CAA AAT GAT TAC AGC TCA CGG GAA TGA ACT TAT CAC CC
<i>papC</i>	GTG GCA GTA TGA GTA ATG ACC GTT A ATA TCC TTT CTG CAG GGA TGC AAT A
<i>sfaS</i>	GTG GAT ACG ACG ATT ACT GTG CCG CCA GCA TTC CCT GTA TTC
<i>focG</i>	CAG CAC AGG CAG TGG ATA CGA GAA TGT CGC CTG CCC ATT GTC
<i>fimH</i>	TGC AGA ACG GAT AAG CCG TGG GCA GTC ACC TGC CCT CCG GTA
<i>sfa/focDE</i>	CTC CGG AGA ACT GGG TGC ATC TTA C CGG AGG AGT AAT TAC AAA CCT GGC A
<i>cnf1</i>	AAG ATG GAG TTT CCT ATG CAG GAG CAT TCA GAG TCC TGC CCT CAT TAT T
<i>hlyA</i>	AAC AAG GAT AAG CAC TGT TCT GGC T ACC ATA TAA GCG GTC ATT CCC GTC A
<i>cdt-s</i>	GAA AGT AAA TGG AAT ATA AAT GTC CG GAA AAT AAA TGG AAC ACA CAT GTC CG
<i>cdt-a</i>	AAA TCA CCA AGA ATC ATC CAG TTA AAA TCT CCT GCA ATC ATC CAG TTT A
<i>colV</i>	CAC ACA CAA ACG GGA GCT GTT CTT CCC GCA GCA TAG TTC CAT
<i>fyuA</i>	TGA TTA ACC CCG CGA CGG GAA CGC AGT AGG CAC GAT GTT GTA
<i>iutA</i>	GGC TGG ACA TCA TGG GAA CTG G CGT CGG GAA CGG GTA GAA TCG
<i>ibeA</i>	AGG CAG GTG TGC GCC GCG TAC TGG TGC TCC GGC AAA CCA TGC
<i>Rfc</i>	ATC CAT CAG GAG GGG ACT GGA AAC CAT ACC AAC CAA TGC GAG
<i>traT</i>	GGT GTG GTG CGA TGA GCA CAG CAC GGT TCA GCG ATC CCT GAG

of 38.9 years. Isolates were identified by MicroScan 4 (Dade Behring) automated system. The presence of β -lactamases and the minimum inhibitory concentration (MIC) were also determined for ampicillin, ampicillin/sulbactam, amoxicillin/clavulanic acid, aztreonam, imipenem, meropenem, piperacillin, piperacillin/tazobactam, ticarcillin/clavulanic acid, amikacin, gentamicin, tobramycin, ceftriaxone, ceftazidime, cefotaxime, cefoxitin, cephalotin, cefazolin, cefepime, cefuroxime, cefotetan, trimethoprim/sulfamethoxazole, ciprofloxacin, gatifloxacin, levofloxacin, and moxifloxacin. The antibiotic resistance was classified into sensitive, resistant, and ESBL (resistance due to β -lactamases). Pure cultures were maintained at -70°C in brain-heart infusion

TABLE 2: PCR conditions for each gene.

Genes	Initial denaturation (°C/min)	Denaturation (°C/s)	Annealing (°C/s)	Extension (°C/s)	Final extension (°C/min)	Cycles
<i>ecpA</i>	96/5	94/30	62/45	72/45	72/5	35
<i>ecpR-B</i>	95/5	95/30	57.5/33	72/90	75/5	35
<i>fimH</i>	96/5	94/30	65.5/30	72/30	72/5	35
<i>papC</i>	95/5	94/30	58.2/30	72/40	72/5	40
<i>sfaS</i>	95/5	94/30	64/30	72/25	72/5	35
<i>fogG</i>	95/5	95/30	64/40	72/30	72/5	30
<i>sfa/focDE</i>	95/5	94/30	65/30	68/40	72/3	35
<i>cnf-1</i>	95/5	94/30	65.5/30	72/30	72/5	35
<i>hlyA</i>	95/5	94/30	63/30	68/60	72/5	30
<i>Multi1*</i>	95/5	94/30	67.1/30	68/160	72/5	30
<i>Multi2**</i>	95/5	94/30	61.5/30	68/180	72/5	35
<i>Rfc</i>	95/5	95/30	62.5/30	72/60	75/5	40

* Multiplex 1 for genes *fyuA*, *iutA* e *ibeA*. ** Multiplex 2 for genes *cdtB*, *cvaC* y *traT*.

broth/glycerol 50%. The *E. coli* CFT073 uropathogenic strain was used as control strain.

2.2. Phylogenetic Groups and Virulence Factors. The PCR was performed with the GoTaq Flexi kit (Promega) according to the manufacturer's instructions. Phylogenetic groups were identified according to Clermont protocol [22]. 16 virulence genes of UPEC were included: *fimH*, *papC*, *sfa/focDE*, *sfaS*, *focG*, *ecpA*, *ecpR-B*, *hlyA*, *cnf-1*, *cdt-B*, *cvaC*, *iutA*, *ibeA*, *rfa*, *traT*, and *fyuA*. PCR primers and conditions for each gene are described in Tables 1 and 2 [5, 17]. The *ecp RB* PCR was performed to overcome the possible variation of *ecpA* which may give a false negative result of the *E. coli* common pilus [17]. All PCR products were visualized in agarose gel stained with ethidium bromide.

2.3. Statistical Analysis. To establish the results significance, the Fisher exact test was used. The level of significance was set at a *P* value of ≤ 0.05 .

3. Results

The overall results of the isolates regarding the virulence genes, the phylogenetic group, and resistance profile are shown in Table 3. Regarding the phylogenetic group, most of the isolates were (60) grouped into the B2 group (55.6%), 33 isolates were classified as part of the A group (30.6%), 10 isolates (9.3%) to group B1, and 5 isolates (4.6%) to group D.

3.1. Virulence Genes. Higher prevalence, above 50%, was observed for the *ecp*, *fimH*, *traT*, *sfa/focDE*, and *papC* genes (98.1%, 86.1%, 77.8%, 74.1%, and 62%, resp.). For *iutA* and *fyuA* genes prevalence was close to 50% (48.1% and 44.4%, resp.), while the *focG*, *sfaS*, *hlyA*, *cnf-1*, *cdt-B*, *cvaC*, *ibeA*, and *rfa* genes registered prevalence lower than 10% (2.8%, 1.9%, 7.4%, 6.5%, 0.9%, 2.8%, 2.8%, and 0.9%, resp.). Table 4 shows the distribution of virulence genes regarding the

phylogenetic group. Most of the virulence factors associated with the phylogenetic group B2 were identified. The *ecp* (A and R-B) and *fimH* genes are widely distributed among all groups (A 100%/78.8%, B1 100%/70%, B2 96.7%/91.7%, and D 100%/100%, resp.). The *focG*, *sfaS*, *hlyA*, *cnf-1*, *cdt-B*, and *cvaC* genes were found only in isolates from the B2 group. The *rfa* gene was found in just one isolate from group B1. The *hlyA*, *cdt-B*, and *traT* genes were positively associated with group B2, and the *iutA* and *fyuA* genes were negatively associated with group A.

3.2. Antibiotic Resistance. Above 50% of antibiotic resistance was observed for ampicillin/sulbactam (75.9%), ampicillin (55.2%), piperacillin (51.1%), trimethoprim/sulfamethoxazole (56.1%), ciprofloxacin (62.3%), gatifloxacin (62.5%), levofloxacin (60.2%), and moxifloxacin (52.6%). Sensitivity values above 50% were found to amoxicillin/clavulanic acid (68.8%), aztreonam (78.4%), imipenem (98.1%), meropenem (100%), piperacillin/tazobactam (86%), ticarcillin/clavulanic acid (58.2%), amikacin (93.5%), gentamicin (72.2%), tobramycin (56.5%), ceftriaxone (78.1%), ceftazidime (77.9%), cefotaxime (78.9%), ceftazidime (91.1%), ceftazidime (65.9%), cefepime (78.1%), cefuroxime (71.1%), and cefotetan (98.4%). Approximately 20% of isolates registered the presence of β -lactamases and around 20% were resistant to antimicrobials, as shown in Table 5. Isolates which displayed resistance to more than ≥ 3 chemotherapeutic groups were considered multiresistant isolates, which represents 58%. However no statistical relation was observed among multiresistance and phylogenetic group (Table 6).

4. Discussion

In this work 108 *E. coli* isolates were screened from female patients with an average age of 39 years; women were regarded as a productive population, for which urinary tract infections are considered a major cause of morbidity in our country and represent a huge economic impact [23, 24].

TABLE 3: Virulence genes and phylogenetic group.

# Strain	Ecp	fimH	papC	sfa/focDE	focG	sfaS	hlyA	cnf-1	cdtB	cvaC	iutA	ibeA	Rfc	traT	fyuA	chuA	yja	TSP	PG
1	+	+	+	+	-	-	-	-	-	+	+	+	-	+	+	+	+	+	B2
2	+	+	-	-	-	-	-	-	-	-	+	-	-	+	+	+	-	-	D
3	+	+	+	-	-	-	-	-	-	-	+	-	-	+	+	+	+	+	B2
4	+	+	+	+	-	-	-	-	-	-	-	-	-	-	-	-	+	-	A
5	+	+	+	+	-	-	-	-	-	-	-	-	-	-	-	-	+	-	A
6	+	+	+	-	-	-	-	-	-	-	+	-	-	+	+	-	+	-	A
7	+	+	+	+	-	-	-	-	-	-	+	-	-	+	+	+	+	-	B2
8	+	-	+	+	-	-	-	-	-	-	+	-	-	+	+	+	+	+	B2
9	+	+	+	+	-	-	-	-	-	-	-	-	-	-	-	-	+	-	A
10	+	+	+	+	-	-	-	-	-	-	-	-	-	+	+	+	+	-	B2
11	+	-	+	+	-	-	-	-	-	-	-	-	-	+	-	-	+	-	A
12	-	+	+	-	-	-	-	-	-	-	+	-	-	+	+	+	+	+	B2
13	+	+	+	+	-	-	-	-	-	-	+	-	-	+	+	+	+	+	B2
14	+	+	+	+	-	-	-	-	-	-	-	-	-	-	-	+	+	-	B2
15	+	-	+	+	-	-	-	-	-	-	+	-	-	+	+	+	+	+	B2
16	+	+	+	+	-	-	-	-	-	-	+	-	-	+	-	-	+	-	A
17	+	+	+	+	-	-	-	-	-	-	+	-	-	+	-	-	+	-	A
18	+	+	+	+	-	-	-	-	-	-	+	-	-	+	+	+	+	-	B2
19	+	+	-	+	-	-	-	-	-	-	+	-	-	+	+	+	+	+	B2
20	+	+	+	+	-	-	-	-	-	-	-	-	-	+	-	-	+	+	B1
21	+	+	+	+	-	-	-	-	-	-	+	-	-	+	+	+	+	-	B2
22	+	+	+	+	-	-	-	-	-	-	-	-	-	+	-	+	+	+	B2
23	+	+	+	+	-	-	-	-	-	-	+	-	-	+	+	-	-	-	A
24	+	+	+	+	-	-	-	-	-	-	-	-	-	+	-	+	+	+	B2
25	+	+	+	+	-	-	-	-	-	-	-	-	-	-	-	-	+	-	A
26	-	+	+	+	-	-	-	-	-	-	-	-	-	+	-	+	+	-	B2
27	+	+	+	+	-	-	-	-	-	-	-	-	-	+	-	+	+	-	B2
28	+	+	-	+	-	-	-	-	-	-	+	-	-	+	+	+	+	+	B2
29	+	+	-	+	-	-	-	-	-	-	-	-	-	-	-	+	-	-	D
30	+	+	+	+	+	-	+	+	-	-	-	-	-	+	+	+	+	+	B2
31	+	+	-	+	-	-	-	-	-	-	+	-	-	+	+	-	+	+	B1
32	+	+	+	+	-	-	+	+	-	-	-	-	-	+	-	+	+	+	B2
33	+	+	-	+	-	-	-	-	-	-	-	-	-	-	-	+	+	-	B2
34	+	+	+	-	-	-	-	-	-	-	-	-	-	+	+	-	+	-	A
35	+	+	-	+	-	-	-	-	-	-	+	-	-	-	+	+	+	+	B2
36	+	+	-	+	-	-	-	-	-	-	-	-	-	+	-	+	-	-	D
37	+	+	+	-	-	-	-	-	-	-	+	-	-	+	+	+	+	+	B2
38	+	+	+	-	-	-	-	-	-	-	-	-	-	+	-	+	+	+	B2
39	+	+	+	+	-	-	-	-	-	-	+	-	-	+	-	+	-	-	D
40	+	+	+	+	-	-	-	-	-	-	-	-	-	+	-	+	+	-	B2
41	+	+	+	-	-	-	-	-	-	-	+	-	-	+	+	+	+	+	B2
42	+	+	-	-	-	-	-	-	-	-	+	-	-	+	+	+	+	+	B2
43	+	+	-	-	-	-	-	-	-	-	-	-	-	+	+	-	-	-	A
44	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	-	A
45	+	+	+	+	-	-	-	-	-	-	-	-	-	-	-	-	+	-	A
46	+	+	+	+	-	-	-	-	-	-	+	-	-	+	+	+	+	-	B2
47	+	+	+	+	-	-	-	-	-	-	+	-	-	+	+	+	+	-	B2
48	+	+	+	+	-	-	-	-	-	-	-	-	-	-	-	-	+	-	A

TABLE 3: Continued.

# Strain	<i>Ecp</i>	<i>fimH</i>	<i>papC</i>	<i>sfa/focDE</i>	<i>focG</i>	<i>sfaS</i>	<i>hlyA</i>	<i>cnf-1</i>	<i>cdtB</i>	<i>cvaC</i>	<i>iutA</i>	<i>ibeA</i>	<i>Rfc</i>	<i>traT</i>	<i>fyuA</i>	<i>chuA</i>	<i>yja</i>	<i>TSP</i>	<i>PG</i>
49	+	+	-	+	-	-	-	-	-	-	-	-	-	+	+	+	+	-	B2
50	+	+	-	+	-	-	-	-	-	-	-	-	-	+	+	-	+	-	A
51	+	+	+	+	-	-	-	-	-	-	-	-	-	-	-	+	+	+	B2
52	+	+	+	+	-	-	-	-	-	-	-	-	-	-	-	-	+	-	A
53	+	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	-	A
54	+	+	+	-	-	-	-	-	-	-	-	-	-	+	+	+	+	-	B2
55	+	+	+	+	+	-	-	-	-	+	+	-	-	+	-	+	+	-	B2
56	+	+	+	+	-	-	-	-	-	-	+	-	-	+	-	-	+	-	A
57	+	+	+	-	-	-	-	-	-	-	+	-	-	+	+	+	+	+	B2
58	+	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	B1
59	+	+	+	+	-	-	-	-	-	-	-	-	-	-	-	+	-	+	D
60	+	-	+	-	-	-	-	-	-	-	+	-	-	-	-	-	+	-	A
61	+	+	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	A
62	+	+	-	-	-	-	-	-	-	-	+	-	-	+	+	+	+	+	B2
63	+	+	+	+	-	-	-	-	-	-	+	-	-	+	+	+	+	+	B2
64	+	+	-	-	-	-	-	-	-	-	+	-	-	+	+	+	+	+	B2
65	+	+	+	-	-	-	-	-	-	-	+	-	-	-	+	+	+	+	B2
66	+	+	+	+	+	-	+	+	-	-	-	-	-	+	-	+	+	+	B2
67	+	+	+	-	-	-	-	-	-	-	-	-	+	-	-	-	+	+	B1
68	+	+	-	+	-	-	-	-	-	-	-	-	-	+	-	+	+	+	B2
69	+	+	+	+	-	-	-	-	-	-	-	-	-	+	-	+	+	-	B2
70	+	+	-	-	-	-	-	-	-	-	-	-	-	+	+	-	+	-	A
71	+	+	+	+	-	-	-	-	-	-	+	-	-	+	-	-	+	-	A
72	+	+	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	A
73	+	+	-	+	-	-	-	-	-	-	-	-	-	+	-	-	+		A
74	+	+	+	+	-	+	+	+	-	-	-	-	-	+	+	+	+	+	B2
75	+	+	-	-	-	-	-	-	-	-	+	-	-	+	+	+	+	-	B2
76	+	-	-	-	-	-	-	-	-	-	-	-	-	+	-	-	+	-	A
77	+	+	-	+	-	-	-	-	-	-	-	-	-	+	+	+	+	-	B2
78	+	+	-	-	-	-	-	-	-	-	-	-	-	+	-	-	+	-	A
79	+	+	-	+	-	-	-	-	-	-	+	-	-	-	-	+	+	-	B2
80	+	+	+	+	-	-	-	-	-	-	-	-	-	-	-	+	+	-	B2
81	+	+	+	+	-	-	-	-	-	-	+	-	-	+	+	+	+	+	B2
82	+	+	-	+	-	-	-	-	-	-	-	-	-	+	+	-	+	-	A
83	+	+	+	+	-	+	+	+	-	-	+	-	-	+	+	+	+	+	B2
84	+	-	+	+	-	-	-	-	-	-	+	-	-	+	-	-	+	-	A
85	+	-	+	+	-	-	-	-	-	-	-	-	-	+	-	-	+	-	A
86	+	+	+	-	-	-	-	-	-	-	+	-	-	+	+	+	+	+	B2
87	+	+	-	-	-	-	-	-	-	-	+	-	-	+	-	-	+	-	A
88	+	+	+	-	-	-	-	-	-	-	-	-	-	+	-	-	+	-	A
89	+	+	-	+	-	-	-	-	-	-	-	-	-	+	+	-	+	+	B1
90	+	+	+	+	-	-	-	-	-	-	+	-	-	+	-	-	+	+	B1
91	+	-	-	+	-	-	-	-	-	-	-	-	-	-	-	-	+	+	B1
92	+	-	+	+	-	-	-	-	-	-	-	-	-	+	-	-	+	+	B1
93	+	+	+	+	-	-	-	-	-	-	-	-	-	+	-	-	+	+	B1
94	+	+	+	+	-	-	-	+	-	-	+	-	-	+	+	+	+	-	B2
95	+	+	+	+	-	-	-	-	-	-	+	-	-	+	+	+	+	+	B2
96	+	+	+	+	-	-	+	-	-	-	+	-	-	+	+	+	+	+	B2
97	+	-	-	+	-	-	-	-	-	-	-	-	-	+	-	-	+	-	A

TABLE 3: Continued.

# Strain	<i>Ecp</i>	<i>fimH</i>	<i>papC</i>	<i>sfa/focDE</i>	<i>focG</i>	<i>sfaS</i>	<i>hlyA</i>	<i>cnf-1</i>	<i>cdtB</i>	<i>cvaC</i>	<i>iutA</i>	<i>ibeA</i>	<i>Rfc</i>	<i>traT</i>	<i>fyuA</i>	<i>chuA</i>	<i>yja</i>	<i>TSP</i>	<i>PG</i>
98	+	+	+	+	-	-	+	+	+	-	+	-	-	+	+	+	+	+	B2
99	+	+	-	+	-	-	-	-	-	-	-	-	-	+	-	+	+	+	B2
100	+	+	-	+	-	-	-	-	-	-	+	-	-	+	+	+	+	+	B2
101	+	+	-	+	-	-	-	-	-	-	+	-	-	+	+	+	+	+	B2
102	+	+	-	-	-	-	-	-	-	-	+	+	-	+	-	-	+	+	B1
103	+	-	-	+	-	-	-	-	-	-	+	-	-	+	-	+	+	-	B2
104	+	-	-	+	-	-	-	-	-	+	+	+	-	+	-	+	+	+	B2
105	+	+	-	+	-	-	+	-	-	-	+	-	-	+	-	+	+	+	B2
106	+	+	-	+	-	-	-	-	-	-	+	-	-	+	-	+	+	+	B2
107	+	-	-	+	-	-	-	-	-	-	-	-	-	+	-	-	+	-	A
108	+	-	-	+	-	-	-	-	-	-	-	-	-	+	-	+	+	+	B2

Phylogenetic group (PG).

TABLE 4: Relation among phylogenetic group and virulence genes.

Gene	Phylogenetic group (n, %)			
	A (n = 33)	B1 (n = 10)	B2 (n = 60)	D (n = 5)
<i>Ecp</i>	33 (100)	10 (100)	58 (96.7)	5 (100)
<i>fimH</i>	26 (78.8)	7 (70)	55 (91.7)	5 (100)
<i>papC</i>	19 (57.6)	6 (60)	40 (66.7)	2 (40)
<i>sfa/focDE</i>	22 (66.7)	7 (60)	47 (78.3)	4 (80)
<i>focG</i>	0	0	3 (5)	0
<i>sfaS</i>	0	0	2 (3.3)	0
<i>hlyA</i>	0	0	8 (13.3) ^a	0
<i>cnf-1</i>	0	0	7 (11.7) ^a	0
<i>cdt-B</i>	0	0	1 (1.7)	0
<i>cvaC</i>	0	0	3 (5)	0
<i>iutA</i>	9 (27.3) ^(a)	3 (30)	38 (63.3) ^a	2 (40)
<i>ibeA</i>	0	1 (10)	2 (3.3)	0
<i>Rfc</i>	0	1 (10)	0	0
<i>traT</i>	21 (63.6)	7 (70)	53 (88.3) ^a	3 (60)
<i>fyuA</i>	7 (21.2) ^(a)	2 (20)	38 (63.3) ^a	1 (20)

^a P values were calculated by comparison of each group with Fisher's exact test.Statistic significance of $\leq 0.05^{(a)}$ negative association.

The predominant phylogenetic group was B2 (55.6%), widely associated with pathogenic strains. In Spain and the United States similar results had been reported and also a lower percentage related to the phylogenetic group D [6–8, 18, 25]. The phylogenetic group A, associated with commensal strains, represents a 30.6%, higher than in other studies, suggesting that the gastrointestinal tract is the main reservoir of strains that may be able to colonize the urinary tract in accordance to previous observations [6, 7, 18, 25]. The B1 group (9.3%) as a cause of urinary tract infections points out the high plasticity of the *E. coli* genome which

allowed the presence of the *fimH*, *papC*, and *ecp* (A and RB) in percentages of 70%, 60%, and 100%, respectively. These genes are related to the ability to colonize the urinary tract epithelium [18, 22, 26–28].

Adhesins genes were present in high percentages: *fimH* (86.1%), *ecp* (A γ R-B) (98.1%), and *papC* (62%), this result could be related to the pathogenicity of the isolated strains as adherence is the most important pathogenicity determinant [4]. The *fimH* gene once again was highly conserved in UTI isolates which confirms its crucial role during colonization of the urinary tract [4, 29–32].

TABLE 5: Antibiotic resistance.

Antibiotic (number of isolates)	S (%)	R (%)	ESBL (%)
ampicillin/sulbactam (108)	26 (24.1)	82 (75.9)	0
ampicillin (97)	22 (22.7)	54 (55.7)	21 (21.9)
amoxicillin/clavulanic acid (64)	44 (68.8)	20 (31.3)	0
aztreonam (97)	76 (78.4)	0	21 (21.6)
Imipenem (108)	106 (98.1)	2 (1.9)	0
Meropenem (30)	30 (100)	0	0
piperacillin/tazobactam (107)	92 (86)	15 (14)	0
piperacillin (95)	25 (26.3)	49 (51.6)	21 (22.3)
ticarcillin/clavulanic acid (91)	53 (58.2)	38 (41.8)	0
amikacin (108)	101 (93.5)	7 (6.5)	0
gentamicin (108)	78 (72.2)	30 (27.8)	0
tobramycin (108)	61 (56.5)	47 (43.5)	0
ceftriaxone (96)	75 (78.1)	0	21 (21.9)
ceftazidime (95)	74 (77.9)	0	21 (22.1)
cefotaxime (76)	60 (78.9)	0	16 (21.1)
cefoxitin (45)	41 (91.1)	4 (8.9)	0
cephalotin (22)	10 (45.5)	8 (36.4)	4 (18.2)
cefazolin (91)	60 (65.9)	11 (12.1)	20 (22)
cefepime (96)	75 (78.1)	0	21 (21.9)
cefuroxime (56)	40 (71.4)	1 (1.8)	15 (26.8)
cefotetan (61)	60 (98.4)	1 (1.6)	0
trimethoprim/sulfamethoxazole (107)	47 (43.9)	60 (56.1)	0
ciprofloxacin (106)	40 (37.7)	66 (62.3)	0
gatifloxacin (64)	24 (37.5)	40 (62.5)	0
levofloxacin (108)	43 (39.8)	65 (60.2)	0
moxifloxacin (19)	9 (47.4)	10 (52.6)	0

TABLE 6: Relation among multidrug resistance and phylogenetic group.

Phylogenetic group	Multidrug resistance [positive isolates number (%)]	
	No-MDS (<i>n</i> = 45)	MDS (<i>n</i> = 63)
A	11 (24.4)	22 (34.9)
B1	6 (13.3)	4 (6.4)
B2	24 (53.3)	36 (57.1)
D	4 (9)	1 (1.6)

MDS: multidrug sensitive. *P* values were calculated by the Fisher's exact test for each group, none has statistical significance value ≤ 0.05 .

The *ecp* (A and RB) gene is associated with commensals and enteropathogenic strains; it was present in 98.1% of this study isolates and according to a similar observation in Portugal it was found in 100% of their isolates; it may be associated with UPEC [17, 22, 24, 28]. The *papC* gene encodes an outer membrane protein essential for the fimbriae P biogenesis regulation. *pap* genes presence had been associated with pyelonephritis; therefore, higher percentages (over 50%) suggest that the strains isolated from the Mexican population have greater capabilities to colonize kidneys and generate pyelonephritis [32, 33].

The *hlyA* and *cnf-1* genes showed a positive relationship with the B2 group; also they are associated with pathogenicity island PAI II₉₆, and the *iutA* gene is associated with

pathogenicity island PAI I_{CFT073} as well as with *hlyA* and *pap* operon [8, 19, 34–36].

The *sfaS* gene was found exclusively in *hlyA* and *cnf-1* positive isolates which could be linked to cystitis cases. This observation is in accordance with the previous report by Lloyd et al. [19].

The *cvaC* gene was present in only three isolates *traT* positive. These genes are both located at the *colV* plasmid. *traT* is related to the phylogenetic group B2, and presumes an animal source. The *iutA* and *fyuA* genes also showed a relation with the phylogenetic group B2 [37–39]. The *ibeA* gene, related to the B2 group, was found in an isolate identified as B1, a result that may start to change the previous assumption [40]. The *rfc* gene was identified in just one isolate which

indicates that the serogroup O4 was not the predominant serogroup in the population studied and that this result may need further serological confirmation [5, 41].

The treatment of choice for ITU is in order of importance: fluoroquinolones (ciprofloxacin), the trimethoprim/sulfamethoxazole, cephalosporins, and penicillins (ampicillin) to which an increasingly developed resistance has been reported due mainly to the indiscriminated antibiotic use [13, 14]. In this work it is confirmed the resistance previously reported values for trimethoprim/sulfamethoxazole (56.1%) [14, 42]; for ciprofloxacin (62.3%), gatifloxacin, levofloxacin, and moxifloxacin, resistance was always above 50%. Positive isolates to *hlyA*, *cnf-1*, and/or *papC* genes were susceptible to fluoroquinolones, results similar to those of Piatti et al. [43]. Besides in Mexico, the previously reported *E. coli* resistance profile included ampicillin, piperacillin, fluoroquinolones, and trimethoprim/sulfamethoxazole which are considered to be first-line choices [13, 44, 45]. Additionally, serotype O25b-ST131 has been reported to be within the Mexican population which has been associated with plasmid mediated quinolone resistance [46]. We had identified multidrug resistance of the *E. coli* strains causing UTI in 58% of the isolates which belonged mainly to group B2, result which kept our attention.

5. Conclusion

This work confirms that most of the isolates associated with urinary tract infections belong to the phylogenetic group B2 and in a lesser extent to group D. Also they displayed a great number of virulence genes. However, commensal strains may also be the cause of UTI. According to our results most parts of the isolates have the ability to colonize the kidneys as they have a high incidence of the *papC* gene. The *hlyA* and *cnf-1* genes encoding toxins and *fyuA* *iutA* and siderophores encoding genes are tightly associated with the phylogenetic group B2.

E. coli has successfully adapted to host's conditions and to the general medical practices as we may observe the high resistance to trimethoprim/sulfamethoxazole and fluoroquinolones, especially on the most frequently isolated phylogenetic groups.

Finally, these results reinforce international knowledge on antimicrobial resistance and the high rate of multidrug resistance found invites us to encourage population awareness of the proper use of antimicrobials.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgment

This work was supported by the *Consejo Nacional de Ciencia y Tecnología*, Grant CONACyT-87586-Salud 2008.

References

- [1] J. B. Kaper, J. P. Nataro, and H. L. T. Mobley, "Pathogenic *Escherichia coli*," *Nature Reviews Microbiology*, vol. 2, no. 2, pp. 123–140, 2004.
- [2] G. Croxall, J. Hale, V. Weston et al., "Molecular epidemiology of extraintestinal pathogenic *Escherichia coli* isolates from a regional cohort of elderly patients highlights the prevalence of ST131 strains with increased antimicrobial resistance in both community and hospital care settings," *Journal of Antimicrobial Chemotherapy*, vol. 66, no. 11, pp. 2501–2508, 2011.
- [3] O. Clermont, S. Bonacorsi, and E. Bingen, "Rapid and simple determination of the *Escherichia coli* phylogenetic group," *Applied and Environmental Microbiology*, vol. 66, no. 10, pp. 4555–4558, 2000.
- [4] M. A. Mulvey, "Adhesion and entry of uropathogenic *Escherichia coli*," *Cellular Microbiology*, vol. 4, no. 5, pp. 257–271, 2002.
- [5] J. R. Johnson and A. L. Stell, "Extended virulence genotypes of *Escherichia coli* strains from patients with urosepsis in relation to phylogeny and host compromise," *The Journal of Infectious Diseases*, vol. 181, no. 1, pp. 261–272, 2000.
- [6] E. Moreno, J. R. Johnson, T. Pérez, G. Prats, M. A. Kuskowski, and A. Andreu, "Structure and urovirulence characteristics of the fecal *Escherichia coli* population among healthy women," *Microbes and Infection*, vol. 11, no. 2, pp. 274–280, 2009.
- [7] E. Moreno, A. Andreu, C. Pigrau, M. A. Kuskowski, J. R. Johnson, and G. Prats, "Relationship between *Escherichia coli* strains causing acute cystitis in women and the fecal *E. coli* population of the host," *Journal of Clinical Microbiology*, vol. 46, no. 8, pp. 2529–2534, 2008.
- [8] D. W. Hilbert, T. E. Paulish, E. Mordechai, M. E. Adelson, and J. P. Trama, "O serogroups, phylogeny, and virulence factors of cervicovaginal and rectal *Escherichia coli* isolates," *European Journal of Clinical Microbiology and Infectious Diseases*, vol. 27, no. 12, pp. 1265–1268, 2008.
- [9] N. Ahmed, U. Dobrindt, J. Hacker, and S. E. Hasnain, "Genomic fluidity and pathogenic bacteria: applications in diagnostics, epidemiology and intervention," *Nature Reviews Microbiology*, vol. 6, no. 5, pp. 387–394, 2008.
- [10] M. Mellata, K. Ameiss, H. Mo, and R. Curtiss III, "Characterization of the contribution to virulence of three large plasmids of avian pathogenic *Escherichia coli* χ 7122 (O78:K80:H9)," *Infection and Immunity*, vol. 78, no. 4, pp. 1528–1541, 2010.
- [11] M. N. Chulain, A.-M. Murray, G. Corbett-Feeney, and M. Cormican, "Antimicrobial resistance in *E. coli* associated with urinary tract infection in the west of Ireland," *Irish Journal of Medical Science*, vol. 174, no. 4, pp. 6–9, 2005.
- [12] J. R. Johnson, M. A. Kuskowski, A. Gajewski, D. F. Sahm, and J. A. Karlowsky, "Virulence characteristics and phylogenetic background of multidrug-resistant and antimicrobial-susceptible clinical isolates of *Escherichia coli* from across the United States, 2000–2001," *The Journal of Infectious Diseases*, vol. 190, no. 10, pp. 1739–1744, 2004.
- [13] J. Molina-López, G. Aparicio-Ozores, R. M. Ribas-Aparicio et al., "Drug resistance, serotypes, and phylogenetic groups among uropathogenic *Escherichia coli* including O25-ST131 in Mexico City," *Journal of Infection in Developing Countries*, vol. 5, no. 12, pp. 840–849, 2011.

- [14] A. Moura, A. Nicolau, T. Hooton, and J. Azeredo, "Antibiotherapy and pathogenesis of uncomplicated UTI: difficult relationships," *Journal of Applied Microbiology*, vol. 106, no. 6, pp. 1779–1791, 2009.
- [15] D. de Backer, T. Christiaens, S. Heytens, A. de sutter, E. E. Stobberingh, and G. Verschraegen, "Evolution of bacterial susceptibility pattern of *Escherichia coli* in uncomplicated urinary tract infections in a country with high antibiotic consumption: a comparison of two surveys with a 10 year interval," *Journal of Antimicrobial Chemotherapy*, vol. 62, no. 2, pp. 364–368, 2008.
- [16] B. K. Hong, H. P. Chi, J. K. Chung, E.-C. Kim, G. A. Jacoby, and D. C. Hooper, "Prevalence of plasmid-mediated quinolone resistance determinants over a 9-year period," *Antimicrobial Agents and Chemotherapy*, vol. 53, no. 2, pp. 639–645, 2009.
- [17] D. Blackburn, A. Husband, Z. Saldaña et al., "Distribution of the *Escherichia coli* common pilus among diverse strains of human enterotoxigenic *E. coli*," *Journal of Clinical Microbiology*, vol. 47, no. 6, pp. 1781–1784, 2009.
- [18] E. Moreno, A. Andreu, T. Pérez, M. Sabaté, J. R. Johnson, and G. Prats, "Relationship between *Escherichia coli* strains causing urinary tract infection in women and the dominant faecal flora of the same hosts," *Epidemiology and Infection*, vol. 134, no. 5, pp. 1015–1023, 2006.
- [19] A. L. Lloyd, D. A. Rasko, and H. L. T. Mobley, "Defining genomic islands and uropathogen-specific genes in uropathogenic *Escherichia coli*," *Journal of Bacteriology*, vol. 189, no. 9, pp. 3532–3546, 2007.
- [20] R. Raz, Y. Gennesin, J. Wasser et al., "Recurrent urinary tract infections in postmenopausal women," *Clinical Infectious Diseases*, vol. 30, no. 1, pp. 152–156, 2000.
- [21] R. Fronzes, H. Remaut, and G. Waksman, "Architectures and biogenesis of non-flagellar protein appendages in Gram-negative bacteria," *The EMBO Journal*, vol. 27, no. 17, pp. 2271–2280, 2008.
- [22] M. A. Rendón, Z. Saldaña, A. L. Erdem et al., "Commensal and pathogenic *Escherichia coli* use a common pilus adherence factor for epithelial cell colonization," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 104, no. 25, pp. 10637–10642, 2007.
- [23] SNdV, "Panorama epidemiológico de las infecciones de vías urinarias en México 2003–2008," *Epidemiológica*, vol. 26, no. 52, 2009.
- [24] Geografía INEGI, "Censo de población y vivienda 2010 panorama sociodemográfico de México," 2011.
- [25] A. Narciso, F. Nunes, T. Amores, L. Lito, J. Melo-Cristino, and A. Duarte, "Persistence of uropathogenic *Escherichia coli* strains in the host for long periods of time: relationship between phylogenetic groups and virulence factors," *European Journal of Clinical Microbiology and Infectious Diseases*, vol. 31, no. 6, pp. 1211–1217, 2012.
- [26] K. Ejrnaes, "Bacterial characteristics of importance for recurrent urinary tract infections caused by *Escherichia coli*," *Danish Medical Bulletin*, vol. 58, no. 4, Article ID B4187, 2011.
- [27] J. D. Sobel, "Pathogenesis of urinary tract infection. Role of host defenses," *Infectious Disease Clinics of North America*, vol. 11, no. 3, pp. 531–549, 1997.
- [28] J. Xicohtencatl-Cortes, V. Monteiro-Neto, M. A. Ledesma et al., "Intestinal adherence associated with type IV pili of enterohemorrhagic *Escherichia coli* O157:H7," *The Journal of Clinical Investigation*, vol. 117, no. 11, pp. 3519–3529, 2007.
- [29] D. M. Guyer, N. W. Gunther IV, and H. L. T. Mobley, "Secreted proteins and other features specific to uropathogenic *Escherichia coli*," *The Journal of Infectious Diseases*, vol. 183, supplement 1, pp. S32–S35, 2001.
- [30] L. Emody, M. Kerényi, and G. Nagy, "Virulence factors of uropathogenic *Escherichia coli*," *International Journal of Antimicrobial Agents*, vol. 22, supplement 2, pp. S29–S33, 2003.
- [31] J. M. Bower, D. S. Eto, and M. A. Mulvey, "Covert operations of uropathogenic *Escherichia coli* within the urinary Tract," *Traffic*, vol. 6, no. 1, pp. 18–31, 2005.
- [32] E.-M. Antao, L. H. Wieler, and C. Ewers, "Adhesive threads of extraintestinal pathogenic *Escherichia coli*," *Gut Pathogens*, vol. 1, article 22, 2009.
- [33] M. C. Lane and H. L. T. Mobley, "Role of P-fimbrial-mediated adherence in pyelonephritis and persistence of uropathogenic *Escherichia coli* (UPEC) in the mammalian kidney," *Kidney International*, vol. 72, no. 1, pp. 19–25, 2007.
- [34] S. Yamamoto, "Molecular epidemiology of uropathogenic *Escherichia coli*," *Journal of Infection and Chemotherapy*, vol. 13, no. 2, pp. 68–73, 2007.
- [35] M. Bingen-Bidois, O. Clermont, S. Bonacorsi et al., "Phylogenetic analysis and prevalence of urosepsis strains of *Escherichia coli* bearing pathogenicity island-like domains," *Infection and Immunity*, vol. 70, no. 6, pp. 3216–3226, 2002.
- [36] S. M. Soto, S. Zúñiga, P. Ulleryd, and J. Vila, "Acquisition of a pathogenicity island in an *Escherichia coli* clinical isolate causing febrile urinary tract infection," *European Journal of Clinical Microbiology and Infectious Diseases*, vol. 30, no. 12, pp. 1543–1550, 2011.
- [37] V. Hancock, L. Ferrières, and P. Klemm, "The ferric yersiniabactin uptake receptor FyuA is required for efficient biofilm formation by urinary tract infectious *Escherichia coli* in human urine," *Microbiology*, vol. 154, no. 1, pp. 167–175, 2008.
- [38] T. E. Clarke, L. W. Tari, and H. J. Vogel, "Structural biology of bacterial iron uptake systems," *Current Topics in Medicinal Chemistry*, vol. 1, no. 1, pp. 7–30, 2001.
- [39] M. C. Rowe, H. L. Withers, and S. Swift, "Uropathogenic *Escherichia coli* forms biofilm aggregates under iron restriction that disperse upon the supply of iron," *FEMS Microbiology Letters*, vol. 307, no. 1, pp. 102–109, 2010.
- [40] D. M. Gordon, O. Clermont, H. Tolley, and E. Denamur, "Assigning *Escherichia coli* strains to phylogenetic groups: multi-locus sequence typing versus the PCR triplex method," *Environmental Microbiology*, vol. 10, no. 10, pp. 2484–2496, 2008.
- [41] S. Lukomski, R. A. Hull, and S. I. Hull, "Identification of the O antigen polymerase (rfc) gene in *Escherichia coli* O4 by insertional mutagenesis using a nonpolar chloramphenicol resistance cassette," *Journal of Bacteriology*, vol. 178, no. 1, pp. 240–247, 1996.
- [42] M. T. Blahna, C. A. Zalewski, J. Reuer, G. Kahlmeter, B. Foxman, and C. F. Marrs, "The role of horizontal gene transfer in the spread of trimethoprim-sulfamethoxazole resistance among uropathogenic *Escherichia coli* in Europe and Canada," *Journal of Antimicrobial Chemotherapy*, vol. 57, no. 4, pp. 666–672, 2006.
- [43] G. Piatti, A. Mannini, M. Balistreri, and A. M. Schito, "Virulence factors in urinary *Escherichia coli* strains: phylogenetic background and quinolone and fluoroquinolone resistance," *Journal of Clinical Microbiology*, vol. 46, no. 2, pp. 480–487, 2008.
- [44] J. L. Arredondo-García and C. F. Amábile-Cuevas, "High resistance prevalence towards ampicillin, co-trimoxazole and ciprofloxacin, among uropathogenic *Escherichia coli* isolates in Mexico City," *Journal of Infection in Developing Countries*, vol. 2, no. 5, pp. 350–353, 2008.

- [45] J. L. Arredondo-García, D. Soriano-Becerril, F. Solórzano-Santos, A. Arbo-Sosa, R. Coria-Jiménez, and P. Arzate-Barbosa, "Resistance of uropathogenic bacteria to first-line antibiotics in Mexico city: a multicenter susceptibility analysis," *Current Therapeutic Research—Clinical and Experimental*, vol. 68, no. 2, pp. 120–126, 2007.
- [46] F. Reyna-Flores, H. Barrios, U. Garza-Ramos et al., "Molecular epidemiology of *Escherichia coli* O25b-ST131 isolates causing community-acquired UTIs in Mexico," *Diagnostic Microbiology & Infectious Disease*, vol. 76, no. 3, pp. 396–398, 2013.